NCT02409316View on ClinicalTrials.gov

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions
Estrogen Receptor Positive Breast CancerBreast NeoplasmMetastatic Breast Cancer
Interventions
DRUG

[18F]FES

\[18F\]FES PET/CT scan

Trial Locations (1)

19104

University of Pennsylvania Hospital, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT02409316 - [18F]FES PET/CT in Endocrine Refractory Breast Cancer | Biotech Hunter | Biotech Hunter